Free Trial
NASDAQ:MRSN

Mersana Therapeutics Q2 2023 Earnings Report

Mersana Therapeutics logo
$0.40 0.00 (-0.58%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.39 -0.01 (-1.94%)
As of 05/2/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Mersana Therapeutics Revenue Results

Actual Revenue
$10.70 million
Expected Revenue
$12.93 million
Beat/Miss
Missed by -$2.23 million
YoY Revenue Growth
+148.80%

Mersana Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Mersana Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Mersana Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Mersana Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mersana Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mersana Therapeutics and other key companies, straight to your email.

About Mersana Therapeutics

Mersana Therapeutics (NASDAQ:MRSN), a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

View Mersana Therapeutics Profile

More Earnings Resources from MarketBeat